<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044745</url>
  </required_header>
  <id_info>
    <org_study_id>083-09</org_study_id>
    <secondary_id>NCI-2009-01552</secondary_id>
    <secondary_id>P30CA036727</secondary_id>
    <nct_id>NCT01044745</nct_id>
  </id_info>
  <brief_title>Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer</brief_title>
  <official_title>RITUXIMAB FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well rituximab works in preventing acute
      graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for
      hematologic cancer. Giving chemotherapy and total-body irradiation before a donor stem cell
      transplant helps stop the growth of cancer cells. It may also stop the patient's immune
      system from rejecting the donor's stem cells. The donated stem cells may replace the
      patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor
      effect). Sometimes the transplanted cells from a donor can also make an immune response
      against the body's normal cells. Giving a monoclonal antibody, rituximab, together with
      anti-thymocyte globulin, tacrolimus, and mycophenolate mofetil before and after the
      transplant may stop this from happening
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the incidence of grade II-IV acute GVHD at day 100 after matched unrelated
      donor allogeneic hematopoietic cell transplantation (HCT) when incorporating rituximab in the
      conditioning regimen.

      SECONDARY OBJECTIVES:

      I. To determine the day 100 transplant related mortality after matched unrelated donor
      allogeneic HCT when incorporating rituximab in the conditioning regimen.

      II. To determine overall survival (OS) and disease-free survival (DFS) after matched
      unrelated donor allogeneic HCT when incorporating rituximab in the conditioning regimen.

      III. To determine the cumulative incidence of infectious complications at day 100 after
      matched unrelated donor HCT when incorporating rituximab in the conditioning regimen.

      IV. To determine the effect of rituximab addition to the conditioning regimen on recovery of
      T regulatory (T-reg) cells, and to determine the effect of T-cell, including T-reg, number in
      the stem cell product and at day 30 on the incidence of grade II-IV acute GVHD (aGVHD) and
      the cumulative infectious complications at day 100.

      V. To determine the effect of rituximab addition to the conditioning regimen on antigen
      presenting myeloid cell recovery, and to determine the effect of dendritic cell subset DC1,
      DC2 and myeloid-derived suppressor cells (MDSC), number in the stem cell graft and at day +30
      on the incidence of acute GVHD grade II-IV and the cumulative incidence of infectious
      complications at day 100.

      OUTLINE:

      CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the
      transplant physician: cyclophosphamide and total-body irradiation (TBI); targeted busulfan
      and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.

      GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab intravenously (IV) on days
      -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients
      also receive tacrolimus IV continuously and then orally (PO) beginning on day -1 and
      continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV
      twice daily on days -1 to 60.

      TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day
      0.

      Patients are followed up periodically for 100 days after transplant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was closed to accrual for safety related to the frequency of BK infections.
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">October 8, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grades II-IV Acute GVHD</measure>
    <time_frame>At day 100</time_frame>
    <description>Determined with death as a competing risk. Defined and staged using the 1994 consensus conference modifications of the Glucksberg criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>From the date of transplant with relapse/progression or death as censored events, up to 2 years</time_frame>
    <description>Estimated using Kaplan-Meier estimator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of transplant with death from any cause as a censored event, up to 2 years</time_frame>
    <description>Estimated using Kaplan-Meier estimator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related Mortality (TRM)</measure>
    <time_frame>At day 100</time_frame>
    <description>Transplant-related mortality (TRM) defined as any mortality after transplantation except mortality from relapsed disease - Reported as a simple percentage.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Contiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Contiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Contiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Contiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Noncontiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage I Adult Burkitt Lymphoma</condition>
  <condition>Stage I Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage I Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage I Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage I Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage I Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage I Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage I Grade 1 Follicular Lymphoma</condition>
  <condition>Stage I Grade 2 Follicular Lymphoma</condition>
  <condition>Stage I Grade 3 Follicular Lymphoma</condition>
  <condition>Stage I Mantle Cell Lymphoma</condition>
  <condition>Stage I Marginal Zone Lymphoma</condition>
  <condition>Stage I Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage I Small Lymphocytic Lymphoma</condition>
  <condition>Stage II Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage II Chronic Lymphocytic Leukemia</condition>
  <condition>Stage II Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage II Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage III Adult Burkitt Lymphoma</condition>
  <condition>Stage III Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage III Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage III Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage III Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage III Grade 1 Follicular Lymphoma</condition>
  <condition>Stage III Grade 2 Follicular Lymphoma</condition>
  <condition>Stage III Grade 3 Follicular Lymphoma</condition>
  <condition>Stage III Mantle Cell Lymphoma</condition>
  <condition>Stage III Marginal Zone Lymphoma</condition>
  <condition>Stage III Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage III Small Lymphocytic Lymphoma</condition>
  <condition>Stage IV Adult Burkitt Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage IV Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage IV Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage IV Grade 1 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 2 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 3 Follicular Lymphoma</condition>
  <condition>Stage IV Mantle Cell Lymphoma</condition>
  <condition>Stage IV Marginal Zone Lymphoma</condition>
  <condition>Stage IV Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Stem cell transplant</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft versus host disease prophylaxis/therapy</intervention_name>
    <description>Undergo graft versus host disease prophylaxis/therapy</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>prophylaxis/therapy, graft versus host disease</other_name>
    <other_name>prophylaxis/therapy, GVHD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
    <description>Undergo graft-versus-tumor induction therapy</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>graft versus host disease induction</other_name>
    <other_name>graft versus tumor induction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>immunosuppressive therapy</intervention_name>
    <description>Undergo immunosuppressive therapy</description>
    <arm_group_label>Treatment (Rituximab and allogeneic HCT transplant)</arm_group_label>
    <other_name>immunosuppression</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic
             myelogenous leukemia (CML) in accelerated phase or blast crisis, chronic lymphocytic
             leukemia (CLL), Non-Hodgkin lymphoma (NHL), myelodysplastic syndromes (MDS)
             (intermediate-2 or high-risk disease by International Pelvic Pain Society [IPPS])

          -  Patients with AML, ALL, or MDS scheduled for myeloablative conditioning should have =&lt;
             10% blasts in bone marrow or peripheral blood at the start of conditioning

          -  Patients with AML, ALL, or CML scheduled for reduced intensity conditioning or
             non-myeloablative conditioning should be in complete morphologic remission at the
             start of conditioning (residual disease by flow cytometry or cytogenetics and/or
             incomplete recovery of neutrophil or platelet count are acceptable)

          -  Patients with CLL or NHL scheduled for reduced intensity or non-myeloablative
             conditioning should have no evidence of bulky disease (&gt; 50% bone marrow involvement
             or masses &gt; 10 cm) at the start of conditioning

          -  Fulfills all pulmonary, cardiac, renal, and hepatic criteria for standard-of-care
             matched unrelated donor (MUD) allogeneic HCT

          -  Men and women of reproductive potential must agree to use an acceptable method of
             birth control during treatment and for twelve months after stem cell transplantation

          -  Adequately matched unrelated donor available

          -  Written informed consent; written informed consent of the unrelated donor is required
             to participate in the optional studies

        Exclusion Criteria:

          -  Patient or donor infected with human immunodeficiency virus (HIV)

          -  Patient or donor with history of hepatitis B or C and/or positive serology consistent
             with previous hepatitis B or C infection (patients and/or donor who received Hepatitis
             B vaccination are acceptable)

          -  Patient or donor with active hepatitis B or C and/or detectable viral ribonucleic acid
             (RNA)

          -  More than 20,000 circulating CD20+ cells/uL

          -  Treatment with rituximab for any reason in the 12 months preceding HCT

          -  Patient scheduled for cord blood transplantation

          -  Presence of active uncontrolled infection at start of conditioning

          -  Presence of active central nervous system (CNS) disease (history of adequately treated
             CNS disease is acceptable)

          -  Presence of uncontrolled psychiatric disorder

          -  Patient unable to give informed consent

          -  Unrelated donor products received from the Deutsche Knochenmarkspenderdatei (DKMS)
             Registry are not eligible for the optional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bociek</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>January 23, 2018</results_first_submitted>
  <results_first_submitted_qc>February 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>R. Gregory Bociek, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Rituximab and Allogeneic HCT Transplant)</title>
          <description>CONDITIONING REGIMEN: Cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Rituximab IV days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
TRANSPLANTATION: Allogeneic hematopoietic stem cell transplantation on day 0.
laboratory biomarker analysis: Correlative studies
graft versus host disease prophylaxis/therapy: Undergo graft versus host disease prophylaxis/therapy
cyclophosphamide: Given PO or IV
fludarabine phosphate: Given IV
busulfan: Given IV
total-body irradiation: Undergo TBI
graft-versus-tumor induction therapy: Undergo graft-versus-tumor induction therapy
immunosuppressive therapy: Undergo immunosuppressive therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineiligible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Rituximab and Allogeneic HCT Transplant)</title>
          <description>CONDITIONING REGIMEN: Cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Rituximab IV days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
TRANSPLANTATION: Allogeneic hematopoietic stem cell transplantation on day 0.
laboratory biomarker analysis: Correlative studies
graft versus host disease prophylaxis/therapy: Undergo graft versus host disease prophylaxis/therapy
cyclophosphamide: Given PO or IV
fludarabine phosphate: Given IV
busulfan: Given IV
total-body irradiation: Undergo TBI
graft-versus-tumor induction therapy: Undergo graft-versus-tumor induction therapy
immunosuppressive therapy: Undergo immunosuppressive therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="21" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grades II-IV Acute GVHD</title>
        <description>Determined with death as a competing risk. Defined and staged using the 1994 consensus conference modifications of the Glucksberg criteria.</description>
        <time_frame>At day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Rituximab and Allogeneic HCT Transplant)</title>
            <description>CONDITIONING REGIMEN: Cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Rituximab IV days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
TRANSPLANTATION: Allogeneic hematopoietic stem cell transplantation on day 0.
laboratory biomarker analysis: Correlative studies
graft versus host disease prophylaxis/therapy: Undergo graft versus host disease prophylaxis/therapy
cyclophosphamide: Given PO or IV
fludarabine phosphate: Given IV
busulfan: Given IV
total-body irradiation: Undergo TBI
graft-versus-tumor induction therapy: Undergo graft-versus-tumor induction therapy
immunosuppressive therapy: Undergo immunosuppressive therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grades II-IV Acute GVHD</title>
          <description>Determined with death as a competing risk. Defined and staged using the 1994 consensus conference modifications of the Glucksberg criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival</title>
        <description>Estimated using Kaplan-Meier estimator.</description>
        <time_frame>From the date of transplant with relapse/progression or death as censored events, up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Rituximab and Allogeneic HCT Transplant)</title>
            <description>CONDITIONING REGIMEN: Cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Rituximab IV days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
TRANSPLANTATION: Allogeneic hematopoietic stem cell transplantation on day 0.
laboratory biomarker analysis: Correlative studies
graft versus host disease prophylaxis/therapy: Undergo graft versus host disease prophylaxis/therapy
cyclophosphamide: Given PO or IV
fludarabine phosphate: Given IV
busulfan: Given IV
total-body irradiation: Undergo TBI
graft-versus-tumor induction therapy: Undergo graft-versus-tumor induction therapy
immunosuppressive therapy: Undergo immunosuppressive therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Estimated using Kaplan-Meier estimator.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Estimated using Kaplan-Meier estimator.</description>
        <time_frame>From the date of transplant with death from any cause as a censored event, up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Rituximab and Allogeneic HCT Transplant)</title>
            <description>CONDITIONING REGIMEN: Cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Rituximab IV days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
TRANSPLANTATION: Allogeneic hematopoietic stem cell transplantation on day 0.
laboratory biomarker analysis: Correlative studies
graft versus host disease prophylaxis/therapy: Undergo graft versus host disease prophylaxis/therapy
cyclophosphamide: Given PO or IV
fludarabine phosphate: Given IV
busulfan: Given IV
total-body irradiation: Undergo TBI
graft-versus-tumor induction therapy: Undergo graft-versus-tumor induction therapy
immunosuppressive therapy: Undergo immunosuppressive therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Estimated using Kaplan-Meier estimator.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant-related Mortality (TRM)</title>
        <description>Transplant-related mortality (TRM) defined as any mortality after transplantation except mortality from relapsed disease - Reported as a simple percentage.</description>
        <time_frame>At day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Rituximab and Allogeneic HCT Transplant)</title>
            <description>CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0.
rituximab: Given IV
mycophenolate mofetil: Given IV or PO
tacrolimus: Given IV
anti-thymocyte globulin: Given IV
allogeneic hematopoietic stem cell transplantation
laboratory biomarker analysis: Correlative studies
graft versus host disease prophyla</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant-related Mortality (TRM)</title>
          <description>Transplant-related mortality (TRM) defined as any mortality after transplantation except mortality from relapsed disease - Reported as a simple percentage.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Rituximab and Allogeneic HCT Transplant)</title>
          <description>CONDITIONING REGIMEN: Cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Rituximab IV days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
TRANSPLANTATION: Allogeneic hematopoietic stem cell transplantation on day 0.
laboratory biomarker analysis: Correlative studies
graft versus host disease prophylaxis/therapy: Undergo graft versus host disease prophylaxis/therapy
cyclophosphamide: Given PO or IV
fludarabine phosphate: Given IV
busulfan: Given IV
total-body irradiation: Undergo TBI
graft-versus-tumor induction therapy: Undergo graft-versus-tumor induction therapy
immunosuppressive therapy: Undergo immunosuppressive therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE">Diarrhea</sub_title>
                <description>Diarrhea</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>vomiting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>thrombotic event</sub_title>
                <description>hepatic veno-occlusive disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders-other</sub_title>
                <description>graft-versus-host disease</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cystitis</sub_title>
                <description>BK virus cystitis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <description>an ANC &lt;1000/mm3 and a single temperature of &gt;38.3 degrees C (101 degrees F) or a sustained temperature of &gt;=38 degrees C (100.4 degrees F) for more than one hour.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <description>disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mucositis - oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune-system disorders- Other</sub_title>
                <description>GVHD -gut</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection and infestation - Other</sub_title>
                <description>Parvovirus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <description>cellulitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>pneumonia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>Failure to thrive</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alanin amintransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <description>A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <description>deep vein thrombosis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>R. Gregory Bociek, MD</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-559-5388</phone>
      <email>rgbociek@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

